ThermoDox To Enter Early Access Program in Europe for Patients with Recurrent Chest Wall Breast Cancer

ThermoDox To Enter Early Access Program in Europe for Patients with Recurrent Chest Wall Breast Cancer
shutterstock_144264631Celsion Corporation has announced it signed an agreement with myTomorrows to implement an Early Access Program for ThermoDox in European Union countries along with Switzerland, to be used in the treatment of recurrent chest wall (RCW) breast cancer patients. This type of breast cancer is considered hard to treat and is associated with a poor prognosis. RCW breast cancer patients that have very resistant tumors will often suffer with metastasis and will not be sensitive to chemotherapy, radiotherapy or hormone therapy. Two recent Phase I clinical trials along with a current Phase II trial have shown that upon combination with thermal therapy, ThermoDox has the potential to significantly improve the overall response rates in refractory patients who have undergone mastectomy. ThermoDox is Celsion's proprietary therapy, consisting of intravenously delivered doxorubicin enhanced with lysolipid thermally sensitive liposomes that upon heating change structure, creating openings in the liposomes to release doxorubicin directly into the targeted tumor. This therapy is currently being investigated in a Phase II clinical trial for recurrent chest wall breast cancer. "We are very excited to make ThermoDox® available to patients with breast cancer who have few options once the tumors have progressed to the chest wall.  Patients with highly resistant tumors found on the chest wall often see their cancer progress despite treatm
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.